Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.59
- Piotroski Score 7.00
- Grade Outperform
- Symbol (TAK)
- Company Takeda Pharmaceutical Company Limited
- Price $13.37
- Changes Percentage (0.3%)
- Change $0.04
- Day Low $13.33
- Day High $13.42
- Year High $15.08
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 09/30/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.29
- Trailing P/E Ratio 46.45
- Forward P/E Ratio 46.45
- P/E Growth 46.45
- Net Income $144.07 B
Income Statement
Quarterly
Annual
Latest News of TAK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Monmouth takes on SFA, aims to end 6-game slide
Monmouth seeks to break a losing streak against SFA. SFA excels in offensive rebounds led by Juhlawnei Stone, while Monmouth struggles on the road. Key players include Kyle Hayman for SFA and Abdi Bas...
By AP NEWS | 21 hours ago -
Weber State takes on UC Irvine following Threatt's 27-point game
Weber State will face UC Irvine after Blaise Threatt's impressive 27-point performance. Weber State had a strong home record of 12-2 and averaged 12.2 assists per game last season....
By AP NEWS | 21 hours ago -
FGCU takes on CSU Bakersfield, aims to end 4-game skid
Receive AP Top 25 Poll Alerts by signing up to get the latest updates. Florida Gulf Coast Eagles face CSU Bakersfield Roadrunners, with FGCU looking to end their four-game losing streak. Last season, ...
By AP NEWS | 21 hours ago
